A detailed history of Jpmorgan Chase & CO transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,255,298 shares of VIR stock, worth $11.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,255,298
Previous 463,247 170.98%
Holding current value
$11.8 Million
Previous $4.69 Million 138.11%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$7.63 - $12.66 $6.04 Million - $10 Million
792,051 Added 170.98%
1,255,298 $11.2 Million
Q1 2024

May 10, 2024

BUY
$8.6 - $11.9 $2.04 Million - $2.82 Million
236,700 Added 104.48%
463,247 $4.69 Million
Q4 2023

Feb 12, 2024

BUY
$7.76 - $10.29 $555,282 - $736,321
71,557 Added 46.17%
226,547 $2.28 Million
Q3 2023

Nov 14, 2023

SELL
$9.14 - $24.62 $717,755 - $1.93 Million
-78,529 Reduced 33.63%
154,990 $1.45 Million
Q2 2023

Aug 11, 2023

BUY
$23.2 - $27.29 $2.49 Million - $2.92 Million
107,164 Added 84.81%
233,519 $5.73 Million
Q1 2023

May 18, 2023

BUY
$22.26 - $30.85 $2.18 Million - $3.02 Million
97,933 Added 344.57%
126,355 $2.94 Million
Q1 2023

May 11, 2023

SELL
$22.26 - $30.85 $2.7 Million - $3.74 Million
-121,197 Reduced 81.0%
28,422 $661,000
Q4 2022

Feb 13, 2023

BUY
$19.96 - $28.22 $1.32 Million - $1.86 Million
65,984 Added 78.9%
149,619 $3.79 Million
Q3 2022

Nov 14, 2022

BUY
$18.26 - $31.1 $12,398 - $21,116
679 Added 0.82%
83,635 $1.61 Million
Q2 2022

Aug 11, 2022

BUY
$19.08 - $26.7 $56,915 - $79,646
2,983 Added 3.73%
82,956 $2.11 Million
Q1 2022

May 11, 2022

SELL
$21.19 - $40.01 $2.16 Million - $4.07 Million
-101,849 Reduced 56.02%
79,973 $2.06 Million
Q4 2021

Feb 10, 2022

SELL
$30.97 - $54.03 $23,351 - $40,738
-754 Reduced 0.41%
181,822 $7.61 Million
Q3 2021

Nov 12, 2021

BUY
$34.9 - $54.54 $6.37 Million - $9.96 Million
182,576 New
182,576 $7.95 Million

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $1.24B
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.